ELEVATED SERUM IL-8, IL-10, IL-22, AND MCP-1 ARE ASSOCIATED WITH INFERIOR CLINICAL OUTCOMES IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
		        
		        	EHA Library, Jun Ho Yi, 
		        			                215082
		            		       
		    
				
			
		        BIOMARKER ANALYSES OF PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, OR RICHTER’S TRANSFORMATION TREATED WITH IBRUTINIB + NIVOLUMAB IN THE PHASE 1/2A LYM1002 STUDY
		        
		        	EHA Library, Anas Younes, 
		        			                215083
		            		       
		    
				
			
		        A PHASE 1B, OPEN-LABEL, DOSE-ESCALATION STUDY OF PRTX-100, A HIGHLY PURIFIED FORM OF STAPHYLOCOCCAL PROTEIN A (SPA), IN ADULT PATIENTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)
		        
		        	EHA Library, Nichola Cooper, 
		        			                215099
		            		       
		    
				
			
		        PHASE II, MULTIPLE-DOSE STUDY OF ANTI-FCRN ANTIBODY, ROZANOLIXIZUMAB (UCB7665), IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: SECOND INTERIM ANALYSIS
		        
		        	EHA Library, Tadeusz Robak, 
		        			                215106
		            		       
		    
				
			
		        SUSTAINED PLATELET COUNTS ≥100X109/L DURING ELTROMBOPAG TREATMENT IN PATIENTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): RESULTS FROM A 2-YEAR, PHASE IV, OPEN-LABEL STUDY
		        
		        	EHA Library, Tahir Shamsi, 
		        			                215119
		            		       
		    
				
			
		        REAL-WORLD OUTCOMES ASSOCIATED WITH LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN THE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA WITHOUT STEM CELL TRANSPLANT
		        
		        	EHA Library, Ajai Chari, 
		        			                215125
		            		       
		    
				
			
		        TG-1701 A NOVEL, ORALLY AVAILABLE, AND COVALENTLY-BOUND BTK INHIBITOR
		        
		        	EHA Library, Emmanuel Normant, PhD, 
		        			                215080
		            		       
		    
				
			
		        AVATROMBOPAG DEMONSTRATES SUPERIORITY TO PLACEBO FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA IN A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
		        
		        	EHA Library, Wojciech Jurczak, 
		        			                215098